Financials
Financial year 2025
IBIS PHARMA from Schaarbeek, company number BE0448505234, closed financial year 2025 with a result of € 561,907 after tax. For that financial year IBIS PHARMA recorded revenue of € 16.9 million and equity of € 4 million. Compared with financial year 2024, the result moved from € 684,904 to € 561,907. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 13, 2026.
€ 4 million
▲ 17% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 561,907
▼ 18% vs 2024
Profit after tax over the fiscal year.
€ 1.6 million
▲ 71% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 3.8 million.
People and assets in 2025
5.8
▼ 0.2 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 447,035
▲ 14% vs 2024
€ 77,100 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 67,675
▼ 42% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 1.7 million
▼ 24% vs 2024
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 40 days on average.
€ 53,683
▼ 61% vs 2024
Wages, holiday pay and social contributions still to pay. No outstanding taxes.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | - | € 15,959,164 | € 17,858,563 | € 16,914,169 | ▼ 5% |
| Gross margin | € 1,217,048 | - | - | - | |
| Profit after taxes | € 676,148 | € 440,750 | € 684,904 | € 561,907 | ▼ 18% |
| Equity | € 3,263,492 | € 3,404,242 | € 3,389,147 | € 3,951,053 | ▲ 17% |
| Total debts | € 2,994,797 | € 2,396,279 | € 3,167,707 | € 1,936,466 | ▼ 39% |
| Cash | € 705,857 | € 1,154,902 | € 944,999 | € 1,616,667 | ▲ 71% |
| Retained profit | € 3,089,124 | € 3,229,874 | € 3,214,779 | € 3,776,685 | ▲ 17% |
| Dividend | € 0 | € 300,000 | € 700,000 | € 0 | ▼ 100% |
| Balance sheet total | € 6,258,290 | € 5,800,521 | € 6,556,853 | € 5,887,519 | ▼ 10% |
| Employees (FTE) | 5.6 | 6 | 6 | 5.8 | ▼ 0.2 |
Key figures of IBIS PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to IBIS PHARMA?
What happened at IBIS PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 561,907 (▼ 18% vs 2024). Source: NBB ↗
- New establishment in Schaarbeek. KBO
- New establishment in Nassogne. KBO
- Start of the company according to the CBE. KBO
In short
From € 676,148 profit in 2022 to € 561,907 profit in 2025.
Paid € 848,358 in corporate taxes since 2022.
Best year ever: 2024, with € 684,904 profit.
On average € 217,300 of value added per employee in 2022.
A new publication or filing at IBIS PHARMA? We notify you, reason included.
Follow IBIS PHARMADatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind IBIS PHARMA are SERGE DASSAS, PHILIPPE MARECHAL and Jean Pierre DELEGLISE. The shares are held by NYOTA INVEST (99.9%), PHILIPPE MARECHAL (0%) and SERGE DASSAS (0%).
Directors
According to the 2025 annual accounts
SERGE DASSAS
Director
Shareholders
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Generaal Wahislaan 20a
1030 Schaarbeek
Generaal Wahislaan 20 A
1030 Schaarbeek
Active since 16 March 1993
Rue du Basteau,Forrières 5
6953 Nassogne
Active since 10 November 1992
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 3 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0448.505.234
- VAT number
- BE 0448.505.234
- Registered office
- Generaal Wahislaan 20a, 1030 Schaarbeek
- Names & denominations
- IBIS PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 27 October 1992
- Peppol
- Active · Active since 1 Jan 2001
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Groothandel in farmaceutische producten
Detailhandel in farmaceutische producten
Apothekers